

資料5 採用文献

- Aboolian, A., Tornambe, R., Ricci, M., & LaRaja, R. D. (1999). Skin necrosis in the presence of paclitaxel and fluorometholone. *Supportive care in cancer*, 7(3), 158-159.
- 我妻恭行 (2005). 正しく・安全に使うための輸液剤・注射剤の必修知識. *エキスパートナース*, 21(4), 59-71.
- Aizawa, H., & Tagami, H. (1987). Delayed tissue necrosis due to mitomycin C. *Acta dermato-venereologica*, 67, 365-366.
- Ajani, J. A., Dodd, L. G., Daugherty, K., Warkentin, D., & Ilson, D. H. (1994). Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. *Journal of the National Cancer Institute*, 86(1), 51-53.
- Aktas, S., Toklu, A. S., & Olgac, V. (2000). Hyperbaric oxygen therapy in adriamycin extravasation: an experimental animal study. *Ann Plast Surg*, 45(2), 167-171.
- Alberts, D. S., & Dorr, R. T. (1991). Case report: topical DMSO for mitomycin-C-induced skin ulceration. *Oncology nursing forum*, 18, 693-695.
- Andersson, A. P., & Dahlstrom, K. K. (1993). Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. *European journal of cancer*, 29A(12), 1712-1714.
- Angel, F. S. (1995). Current controversies in chemotherapy. *Journal of Intravenous Nursing*, 18(1), 16-23.
- Argenta, L. C., & Manders, E. K. (1983). Mitomycin C extravasation injuries. *Cancer*, 51, 1080-1082.
- Arias, D., Requena, L., Hasson, A., Gutierrez, M., Domine, M., Martin, L., & Barat, A. (1991). Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. *Journal of cutaneous pathology*, 18(5), 344-346.
- Averbuch, S. D., Boldt, M., Gaudiano, G., Stern, J. B., Koch, T. H., & Bachur, NR (1988). Experimental chemotherapy-induced skin necrosis in swine. Mechanistic studies of anthracycline antibiotic toxicity and protection with a radical dimer compound. *The Journal of clinical investigation*, 81(1), 142-148.
- Averbuch, S. D., Gaudiano, G., Koch, T. H., & Bachur, N. R. (1986). Doxorubicin-induced skin necrosis in the swine model: protection with a novel radical dimer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 4(1), 88-94.
- Aytekin, F. O., Tekin, K., Kocaoglu, H., & Erdem, E. (2002). An alternative method for preventing extravasation complications in vascular access catheters with reservoirs

- for subcutaneous infusion: the double injection technique. *Tumori*, 88(5), 411-413.
- Bairey, O., Bishara, J., Stahl, B., & Shaklai, M. (1997). Severe tissue necrosis after cisplatin extravasation at low concentration: possible "immediate recall phenomenon". *Journal of the National Cancer Institute*, 89(16), 1233-1234.
- Ballarini, C., Intra, M., Pisani Ceretti, A., Cordovana, A., Pagani, M., Farina, G., & Perrone, S., et al. (1999). Complications of subcutaneous infusion port in the general oncology population. *Oncology*, 56(2), 97-102.
- Baranowski, L. (1993). Central venous access devices: current technologies, uses, and management strategies. *Journal of intravenous nursing*, 16(3), 167-194.
- Barden, G. A. (1980). Venous extravasation of doxorubicin HCl with secondary skin ulceration. *Southern medical journal*, 73(11), 1543-1544.
- Barrios, C. H., Zuke, J. E., Blaes, B., Hirsch, J. D., & Lyss, A. P. (1992). Evaluation of an implantable venous access system in a general oncology population. *Oncology*, 49(6), 474-478.
- Bartkowski-Dodds, L., & Daniels, J. R. (1980). Use of sodium bicarbonate as a means of ameliorating doxorubicin-induced dermal necrosis in rats. *Cancer chemotherapy, & pharmacology*, 4(3), 179-181.
- Barutca, S., Kadikoylu, G., Bolaman, Z., Meydan, N., & Yavasoglu, I. (2002). Extravasation of paclitaxel into breast tissue from central catheter port. *Supportive care in cancer*, 10(7), 563-565.
- Baur, M., Kienzer, H. R., Rath, T., & Dittrich, C. (2000). Extravasation of Oxaliplatin (Eloxatin®) - Clinical Course. *Onkologie*, 23(5), 468-471.
- Beason, R. (1990). Antineoplastic vesicant extravasation. *Journal of intravenous nursing : the official publication of the Intravenous Nurses Society*, 13(2), 111-114.
- Beri, R., Rosen, F. R., Pacini, M. J., & Desai, S. R. (2003). Severe dermatologic reactions at multiple sites after paclitaxel administration. *The Annals of pharmacotherapy*, 38(2), 238-241.
- Bertelli, G. (1995). Prevention and management of extravasation of cytotoxic drugs. *Drug safety : an international journal of medical toxicology and drug experience*, 12(4), 245-255.
- Bertelli, G., Dini, D., Forno, G. B., Gozza, A., Silvestro, S., Venturini, M., Rosso, R., & Pronzato, P. (1994). Hyaluronidase as an antidote to extravasation of Vinca alkaloids: clinical results. *Journal of cancer research and clinical oncology*, 120(8), 505-506.
- Bertelli, G., Gozza, A., Forno, G. B., Vidili, M. G., Silvestro, S., Venturini, M., Del Mastro, L., Garrone, O., Rosso, R., & Dini, D. (1995). Topical dimethylsulfoxide for

- the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 13(11), 2851-2855.
- Betcher, D. (1987). Local toxicities of chemotherapy. *Journal of the Association of Pediatric Oncology Nurses*, 4(1-2), 56-60.
- Bhawan, J., Petry, J., & Rybak, M. E. (1989). Histologic changes induced in skin by extravasation of doxorubicin (adriamycin). *Journal of cutaneous pathology*, 16(3), 158-163.
- Bicher, A., Levenback, C., Burke, T. W., Morris, M., Warner, D., DeJesus, Y., & Gershenson, D. M. (1995). Infusion site soft-tissue injury after paclitaxel administration. *Cancer*, 76(1), 116-120.
- Blum, R. H., Garnick, M. B., Israel, M., Canellos, G. P., Henderson, I. C., & Frei, E., 3rd. (1979). Initial clinical evaluation of N-trifluoroacetyl-adriamycin-14-valerate (AD-32), an adriamycin analog. *Cancer treatment reports*, 63(5), 919-923.
- 朴常秀他 (1996). 抗癌剤の血管外漏出. *医薬ジャーナル*, 32(2), 611-615.
- Boman, N. L., Tron, V. A., Bally, M. B., & Cullis, P. R. (1996). Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. *Cancer chemotherapy, & pharmacology*, 37(4), 351-355.
- Bothe, A., Jr., Piccione, W., Ambrosino, J. J., Benotti, P. N., & Lokich, J. J. (1984). Implantable central venous access system. *American journal of surgery*, 147(4), 565-569.
- Bowers, D. G., & Lynch, J. B. (1978). Adriamycin extravasation. *Plast. Reconstr. Surgery*, 61, 86-92.
- Boyle, D., & Engelking, C. (1995). Vesicant extravasation: Myth and realities. *Oncology Nursing Forum*, 22, 57-65.
- Bozkurt, A. K., Uzel, B., Akman, C., Ozguroglu, M., Molinas, & Mandel, N. (2003). Intrathoracic extravasation of antineoplastic agents: case report and systematic review. *American journal of clinical oncology*, 26(2), 121-123.
- Brown, C. V., & Miller, J. H. (1994). Extraskeletal localization of MDP in soft tissue secondary to methotrexate infiltration. *Clinical nuclear medicine*, 19(4), 357-358.
- Brown, D. F., Muirhead, M. J., Travis, P. M., Vire, S. R., Weller, J., & Hauer-Jensen, M. (1997). Mode of chemotherapy does not affect complications with an implantable venous access device. *Cancer*, 80(5), 966-972.
- Brucher, B. L., Stock, K., Weiss, W., Ungeheuer, A., Erdmann, J., & Lersch, C. (2005). Noninvasive power Doppler-mediated diagnosis of catheter leakage in a totally implanted venous access port. *Journal of ultrasound in medicine*, 24(1), 109-111.

- Buchanan, G. R., Buchsbaum, H. J., O'Banion, K., & Gojer, B. (1985). Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model. *Medical and pediatric oncology*, 13(6), 375-380.
- Camp-Sorrell, D. (1998). Developing extravasation protocols and monitoring outcomes. *Journal of intravenous nursing: the official publication of the Intravenous Nurses Society*, 21(4), 232-239.
- Carde, P., Cosset-Delaigue, M. F., Laplanche, A., & Chareau, I. (1989). Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors. *European journal of cancer & clinical oncology*, 25(6), 939-944.
- Cathcart-Rake, W. F., & Mowery, W. E. (1991). Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter. *Cancer*, 67(3), 735-737.
- Champault, G. (1986). Totally implantable catheters for cancer chemotherapy: French experience on 325 cases. *Cancer drug delivery*, 3(2), 131-137.
- Chrystal, C. (1997). Administering continuous vesicant chemotherapy in the ambulatory setting. *Journal of intravenous nursing*, 20(2), 78-88.
- Chu, C. Y., Yang, C. H., Yang, C. Y., Hsiao, G. H., & Chiu, H. C. (2000). Fixed erythrocyte aggregation plaque due to intravenous injection of docetaxel. *The British journal of dermatology*, 142(4), 808-811.
- Cicchetti, S., Jemec, B., & Gault, D. T. (2000). Two case reports of vinorelbine extravasation: management and review of the literature. *Tumori*, 86(4), 289-292.
- Clark, B. S., Gallegos, E., & Bleyer, W. A. (1997). Accidental intramuscular vincristine: lack of untoward effects and recommendations for management. *Medical and pediatric oncology*, 28(4), 314-315.
- Cohen, F. J., Manganaro, J., & Bezozo, R. C. (1983). Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. *The Journal of hand surgery*, 8(1), 43-45.
- Cohen, M. H. (1979). Amelioration of adriamycin skin necrosis: an experimental study. *Cancer treatment reports*, 63(6), 1003-1004.
- Coleman, J. J., 3rd., Walker, A. P., & Didolkar, M. S. (1983). Treatment of adriamycin-induced skin ulcers: a prospective controlled study. *Journal of surgical oncology*, 22(2), 129-135.
- Comas, D., & Mateu, J. (1996). Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. *The Annals of pharmacotherapy*, 30(3), 244-246.

- Curran, C. F., & Luce, J. K. (1990). Extravasation of doxorubicin from vascular access devices. *Sel Cancer Ther*, 6(2), 103-107.
- Curran, C. F., Luce, J. K., & Page, J. A. (1990). Doxorubicin-associated flare reactions. *Oncology nursing forum*, 17(3), 387-389.
- Dahlstrom, K. K., Chenoufi, H. L., & Daugaard, S. (1990). Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation. *Experimental and clinical studies. Cancer*, 65(8), 1722-1726.
- Daugherty, JP., & Khurana, A. (1985). Amelioration of doxorubicin-induced skin necrosis in mice by butylated hydroxytoluene. *Cancer chemotherapy and pharmacology*, 14(3), 243-246.
- Desai, M. H., & Teres, D. (1982). Prevention of doxorubicin-induced skin ulcers in the rat, & pig with dimethyl sulfoxide (DMSO). *Cancer treatment reports*, 66(6), 1371-1374.
- Diekmann, J., & Ransom, J. (1985). Extravasation of doxorubicin from a Hickman catheter: a case presentation. *Oncology nursing forum*, 12(6), 50-52.
- Dini, D., Forno, G., Gozza, A., Silvestro, S., Bertelli, G., Toma, S., Filippi, F., & Passarelli, B. (1995). Combined management in the treatment of epidoxorubicin extravasation. A case report. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*, 3(2), 150-152.
- Disa, J. J., Chang, R. R., Mucci, S. J., & Goldberg, N. H. (1998). Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration. *Plastic and reconstructive surgery*, 101(2), 370-374.
- Doll, D. C., & Yarbro, J. W. (1992). Vascular toxicity associated with antineoplastic agents. *Seminars in oncology*, 19(5), 580-596.
- Dorr, R. T., & Alberts, D. S. (1981). Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. *Cancer treatment reports*, 65(11-12), 1001-1006.
- Dorr, R. T., & Alberts, D. S. (1983). Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. *Cancer treatment reports*, 67(5), 499-501.
- Dorr, R. T., & Alberts, D. S. (1985). Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse. *Journal of the National Cancer Institute*, 74(1), 113-120.
- Dorr, R. T., & Bool, K. L. (1995). Antidote studies of vinorelbine-induced skin ulceration in the mouse. *Cancer chemotherapy and pharmacology*, 36(4), 290-292.
- Dorr, R. T., Alberts, D. S., & Chen, H. S. (1980). Experimental model of doxorubicin extravasation in the mouse. *Journal of pharmacological methods*, 4(3), 237-250.

- Dorr, R. T., Alberts, D. S., & Stone, A. (1985). Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse. *Cancer treatment reports*, 69(4), 431-437.
- Dorr, R. T., Dordal, M. S., Koenig, L. M., Taylor, C. W., & McCloskey, T. M. (1989). High levels of doxorubicin in the tissues of a patient experiencing extravasation during a 4-day infusion. *Cancer*, 64(12), 2462-2464.
- Dorr, R. T., Snead, K., & Liddil, J. D. (1996). Skin ulceration potential of paclitaxel in a mouse skin model in vivo. *Cancer*, 78(1), 152-156.
- Dorr, R. T. (1981). Extravasation of vesicant antineoplastics: clinical and experimental findings. *Arizona medicine*, 38(4), 271-275.
- Dorr, R. T., & Jones, S. E. (1979). Inapparent infiltrations associated with vindesine administration. *Medical and pediatric oncology*, 6(4), 285-288.
- Dorr, R. T., Alberts, D. S., & Chen, H. S. (1980). The limited role of corticosteroids in ameliorating experimental doxorubicin skin toxicity in the mouse. *Cancer chemotherapy and pharmacology*, 5(1), 17-20.
- Dorr, R. T., Alberts, D. S., Einspahr, J., Mason-Liddil, N., & Soble, M. (1987). Experimental dacarbazine antitumor activity, & skin toxicity in relation to light exposure, & pharmacologic antidotes. *Cancer treatment reports*, 71(3), 267-272.
- El, Saghir, N. S., & Otrock, Z. K. (2004). Docetaxel extravasation into the normal breast during breast cancer treatment. *Anticancer Drugs*, 15(4), 401-404.
- 遠藤久美 (2003). 抗癌剤の経静脈投与. *EB NURSING*, 3(3), 319-324.
- Ener, R. A., Meglathery, S. B., & Styler, M. (2004). Extravasation of systemic hemato-oncological therapies. *Annals of oncology*, 15(6), 858-862.
- Eroglu, E., Sari, A., Altuntas, I., Delibas, N., Candir, C., & Agalar, F. (2000). The effect of GM-CSF (granulocyte macrophage colony stimulating factor) on doxorubicin induced tissue necrosis and wound healing. *Indian journal of cancer*, 37(4), 153-157.
- Fitzpatrick, J. E. (1992). New histopathologic findings in drug eruptions. *Dermatologic clinics*, 10(1), 19-36.
- Fu, K. K., & Lam, K. N. (1991). Early and late effects of mitomycin C and continuous low-dose-rate irradiation on the mouse skin and soft tissues of the leg. *International journal of radiation oncology, biology, physics*, 21(6), 1523-1528.
- Gaze, N. R. (1978). Tissue necrosis caused by commonly used intravenous infusions. *Lancet*, 2(8086), 417-419.
- Guenier, C., Ferreira, J., & Pector, J. C. (1989). Prolonged venous access in cancer patients. *European journal of surgical oncology*, 15(6), 553-555.
- Gullatte, M. M. (2001). Principles and Standards of Chemotherapy Administration *Clinical Guide to Antineoplastic Therapy: A chemotherapy Handbook*, 31-45.

- Hajarizadeh, H., Lebrede, L., Barrie, R., & Woltering, E. A. (1994). Protective effect of doxorubicin in vitamin C or dimethyl sulfoxide against skin ulceration in the pig. *Annals of surgical oncology: the official journal of the Society of Surgical Oncology*, 1(5), 411-444.
- Hall, P., Cedermark, B., & Swedenborg, J. (1989). Implantable catheter system for long-term intravenous chemotherapy. *Journal of surgical oncology*, 41(1), 39-41.
- Hankin, F. M., & Louis, D. S (1984). Surgical management of doxorubicin (Adriamycin) extravasation. *Journal of pediatric orthopedics*, 4(1), 96-99.
- Hankin, F. M., & Louis, D. S. (1985). Extravasation of chemotherapeutic agents. *American family physician*, 31(3), 147-150.
- Harwood, K. V., & Bachur, N. (1987). Evaluation of dimethyl sulfoxide and local cooling as antidotes for doxorubicin extravasation in a pig model. *Oncology nursing forum*, 14(1), 39-44.
- 長谷川泰男他 (1992). 抗癌剤の血管外漏出に対する初期治療について. *日本形成外科学会誌*, 12(5), 299-306.
- Hecker, J. F. (1990). Survival of intravenous chemotherapy infusion sites. *Br J Cancer* , 62(4), 660-662.
- Heitmann, C, Durmus, C., & Ingianni, G. (1998). Surgical management after doxorubicin and epirubicin extravasation. *Journal of hand surgery (Edinburgh, Lothian)*, 23(5), 666-668.
- Herrington, J. D., & Figueroa, J. A. (1997). Severe necrosis due to paclitaxel extravasation. *Pharmacotherapy*, 17(1), 163-165.
- Hirai, K., Ishiko, O., Nakajima, S., Kanaoka, Y., Nakamura, Y., Oiso, N., Ishii, M., & Ogita, S. (2002). Local erythematous dermatitis after intravenous docetaxel. *Gynecologic and obstetric investigation*, 53(2), 118-120.
- Ignoffo, R. J., & Friedman, M. A. (1980). Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. *Cancer Treatment Reports*, 7, 17-27.
- Ignoffo, R. J., & Friedman, M. A. (1980). Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. *Cancer treatment reviews*, 7(1), 17-27.
- 飯野京子, 坂本照美 (2003). 皮膚障害・漏出性皮膚炎のセルフケア支援. *看護学雑誌*, 67(11), 1077-1083.
- 石田陽子他 (2003). 点滴漏れに対するリバノール(アクリノール)湿布の効果に関する実験的研究. *日本看護科学学会抄録集*, 23, 125.
- 石田陽子他 (2004). 薬剤漏出による皮膚組織傷害に対するアクリノール湿布の効果に関

- する実験的研究. 日本看護技術学会誌, 3(1), 58-65.
- 石原和之他 (1992). 抗癌剤の血管外漏出とその対策. *Skin Cancer*, 7(1), 117-128.
- Ishihara, K. (2003). [The skin and alopecia]. *Nippon rinsho: Japanese journal of clinical medicine*, 61(6), 1001-1005.
- Jenkins, J., & Corden, B. J. (1983). Vesicant activity of chemotherapeutic agents. *Cancer treatment reports*, 67(4), 409.
- Jensen, J. N., Lock-andersen, J., Langer, S. W., & Mejer, J. (2003). Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines. *Scandinavian journal of plastic and reconstructive surgery and hand surgery / Nordisk plastikkirurgisk forening [and] Nordisk klubb for handkirurgi*, 37(3), 174-175.
- 金井久子 (2004). 乳がん化学療法 of 副作用と対処方法の教育. *看護技術*, 50(3), 226-231.
- 神田清子他 (1988). 抗腫瘍剤溢出時の湿布の効果: ウサギを用いた病理組織学的変化. *看護展望*, 13(3), 76-83.
- 金児玉青 (2004). がん化学療法の看護⑩ 抗がん剤の安全な取り扱い② 血管外漏出. *月刊ナーシング*, 24(1), 88-93.
- Karakousis, C. P., Rao, U., Holtermann, O. A., Kanter, P. M., & Holyoke, E. D. (1979). Tourniquet infusion chemotherapy in extremities with malignant lesions. *Surg Gynecol Obstet*, 149(4), 481-90.
- Khan, M. S., & Holmes, J. D. (2002). Reducing the morbidity from extravasation injuries. *Annals of plastic surgery*, 48(6), 628-632.
- Khanna, A. K., Khanna, A., Asthana, A. K., & Misra, M. K. (1985). Mitomycin C extravasation ulcers. *Journal of surgical oncology*, 28(2), 108-110.
- 木邑道夫 (1994). 安全で有効な処方のための医薬品情報(2). *Pharma Medica*, 12(12), 132-134.
- 北村彰英他 (1994). 抗癌剤の血管外漏出による皮膚潰瘍のような治療と対策. *南大阪病院医学雑誌*, 42(1), 1-11,13,15,17.
- Kock, H. J., Pietsch, M., Krause, U., Wilke, H., & Eigler, F. W. (1998). Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. *World journal of surgery*, 22(1), 12-16.
- 小坂正明他 (2002). 抗癌剤漏出による深達性皮膚潰瘍に対するフィブラストスプレーの使用経験. *診療と新薬*, 39(2), 100-104.
- 河野勤 (2002). 抗がん剤を末梢血管から点滴投与しているのですが・痛みがあります. *看護学雑誌*, 66(5), 424-427.
- Krasnow, S. H., Rhodes, G., Boyer, M., Citron, M. L., Gaspar, O., Johnston-Early, A., & Cohen, M. H. (1985). Hickman catheter tip displacement. *The Southern medical*

- journal, 78(11), 1327-1329.
- Kumar, R. J., Pegg, S. P., & Kimble, R. M. (2001). Management of extravasation injuries. *ANZ journal of surgery*, 71(5), 285-289.
- 黒川由美他 (1998). 診療上のアクシデント インフォームドコンセント・予防・対処 治療行為 静注薬の血管外漏出. *小児科*, 別冊, 103-106.
- Labourey, J. L., Lacroix, P., Genet, D., Gobeaux, F., Martin, J., Venat-Bouvet, L., & Lavau-Denes, S., et al. (2004). Thrombotic complications of implanted central venous access devices: prospective evaluation. *Bulletin du cancer*, 91(5), 431-436.
- Lambert, M. E., Chadwick, G. A., McMahon, A., & Scarffe, J. H. (1988). Experience with the Portacath. *Hematological oncology*, 6(1), 57-63.
- Langer, S. W., Sehested, M., & Jensen, P. B. (2000). Treatment of anthracycline extravasation with dexrazoxane. *Clinical Cancer Research*, 6(9), 80-87.
- Langstein, H. N., Duman, H., Seelig, D., Butler, C. E., & Evans, G. R. (2002). Retrospective study of the management of chemotherapeutic extravasation injury. *Annals of plastic surgery*, 49(4), 369-374.
- Larson, D. L. (1982). Treatment of tissue extravasation by antitumor agents. *Cancer*, 49, 1796-1799.
- Larson, D. L. (1985). What is the appropriate management of tissue extravasation by antitumor agents? *Plastic and reconstructive surgery*, 75(3), 397-405.
- Larson, D. L. (1990). Alterations in wound healing secondary to infusion injury. *Clinics in plastic surgery*, 17(3), 509-517.
- Laughlin, R. A., Landeen, J. M., & Habal, M. B. (1979). The management of inadvertent subcutaneous adriamycin infiltration. *American journal of surgery*, 137, 408-412.
- Laurie, S. W., Wilson, K. L., Kernahan, D. A., Bauer, B. S., & Vistnes, L. M. (1984). Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. *Annals of plastic surgery*, 13(3), 191-194.
- Lebrede, L., Barrie, R., & Woltering, E. A. (1992). DMSO protects against adriamycin-induced tissue necrosis. *The journal of surgical research*, 53, 62-65.
- Lemmers, N. W., Gels, M. E., Sleijfer, D. T., Plukker, J. T., van der Graaf, W. T., de Langen, Z. J., Droste, J. H., Koops, H. S., & Hoekstra, H. J. (1996). Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 14(11), 2916-2922.
- Leonard, G. D., & Zujewski, J. A. (2003). Docetaxel-related skin, nail, and vascular toxicity. *The Annals of pharmacotherapy*, 37(1), 148.

- Leong, D. C., Craft, P. S., & Prosser, I. W. (1996). Phrenic nerve palsy due to chemotherapy extravasation from a Hickman catheter. *Australian and New Zealand journal of medicine*, 26(1), 112-113.
- Levin, M., Caravone, D., & Geiser, C. (1996). Mitoxantrone extravasation and tissue necrosis. *American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists*, 53(10), 1192-1194.
- Linder, R. M., & Upton, J. (1985). Prevention of extravasation injuries secondary to doxorubicin. *Postgraduate medicine*, 77(4), 105-9,112,114.
- Linder, R. M., Upton, J., & Osteen, R. (1983). Management of extensive doxorubicin hydrochloride extravasation injuries. *The Journal of hand surgery*, 8(1), 32-34.
- Lokich, J. J., Bothe, A., Jr., Benotti, P., & Moore, C. (1985). Complications and management of implanted venous access catheters. *Journal of clinical oncology*, 3(5), 710-717.
- Lotem, M., Hubert, A., Lyass, O., Goldenhersh, M. A., Ingber, A., Peretz, T., & Gabizon, A. (2000). Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. *Archives of dermatology*, 136(12), 1475-1480.
- Loth, T. S. (1986). Minimal surgical debridement for the treatment of chemotherapeutic agent-induced skin extravasations. *Cancer treatment reports*, 70(3), 401-404.
- Loth, T. S., & Eversmann, W. W., Jr. (1986). Treatment methods for extravasations of chemotherapeutic agents: a comparative study. *The Journal of hand surgery*, 11(3), 388-396.
- Lubejko, B. G., & Sartorius, S. E. (1993). Nursing considerations in paclitaxel (Taxol) administration. *Seminars in oncology*, 20(4 Suppl 3), 26-30.
- Lucero, M. J., Vigo, J., Rabasco, A. M., Sanchez, J. A., & Martin, F. (1993). Protection by alpha-tocopherol against skin necrosis induced by doxorubicin hydrochloride. *Die Pharmazie*, 48(10), 772-775.
- Lynch, D. J., Key, J. C., White, R. R. 4th. (1979). Management and prevention of infiltration and extravasation injury. *The Surgical clinics of North America*, 59(5), 939-949.
- MacCara, M. E. (1983). Extravasation: A hazard of intravenous therapy. *Drug intelligence & clinical pharmacy*, 17, 713-717.
- Mamakos, M. S. (1984). Recall phenomenon or severe skin and muscle necrosis following Adriamycin extravasation in the hand. *International surgery*, 69(1), 73-74.
- Manheimer, F., Aranda, C. P., & Smith, R. L. (1992). Necrotizing pneumonitis caused by 5-fluorouracil infusion. A complication of a Hickman catheter. *Cancer*, 70(2),

554-556.

- Mansour, A., & Nelson, D. S. (1979). Effect of hydrocortisone, cyclophosphamide, azathioprine and methotrexate on cutaneous delayed and arthus hypersensitivity in the rat. *International archives of allergy and applied immunology*, 60(1), 50-59.
- Marnocha, R. S., & Hutson, P. R. (1992). Intradermal carboplatin and ifosfamide extravasation in the mouse. *Cancer*, 70(4), 850-853.
- Mateu, J., & Llop, C. (1994). Delayed treatment of vindesine extravasation. *The Annals of pharmacotherapy*, 28(7-8), 967-968.
- 松葉祥一他 (2004). 抗がん剤による有害反応: その予防と処置 血管外への漏出による組織壊死. *血液・腫瘍科*, 49(5), 471-475.
- 松永若利, 草場辰哉, 市村信一, 吉村浩二 (1987). 抗腫瘍剤の血管外漏出による皮膚障害について. *臨床皮膚科*, 41(3), 265 - 269.
- Mayo, D. J. (1998). Fibrin sheath formation and chemotherapy extravasation: a case report. *Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer*, 6(1), 51-56.
- Mayo, D. J., & Pearson, D. C. (1995). Chemotherapy extravasation: a consequence of fibrin sheath formation around venous access devices. *Oncology nursing forum*, 22(4), 675-680.
- McCaffrey, D. B. & Engelking, C. (1996). ビシカントの血管外漏出—神話と現実 (海外誌から *Oncology Nursing Forum* 22(1)) *がん看護*, 1(2), 137-150.
- Meehan, J. L., & Sporn, J. R. (1994). Case report of Taxol administration via central vein producing a recall reaction at a site of prior Taxol extravasation. *Journal of the National Cancer Institute*, 86(16), 1250-1251.
- Mehta, P., & Najjar, N. (1978). Skin ulceration due to faulty adriamycin administration. *Clinical pediatrics*, 17(8), 663-664.
- 三浦奈都子他 (2003). 薬剤漏出に対する罨法の効果についての実験的研究. *日本看護科学学会誌*, 23(3), 48-56.
- Moore, C., Strong, D., & Childress, J (1996). Surveillance of the Patient Receiving Infusional Cancer Chemotherapy: Nursing Role in Recognition and Management of Catheter-Related Complications. *Journal of Infusional Chemotherapy*, 6(4), 171-180.
- Mueller, B. U., Skelton, J., Callender, D. P., Marshall, D., Gress, J., Longo, D., & Norton, J., et al. (1992). A prospective randomized trial comparing the infectious, & noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. *Journal of clinical oncology*, 10(12), 43-48.
- Murakami, Y., Shibata, S., Koso, S., Nagae, S., & Furue, M. (2000). Delayed tissue necrosis associated with mitomycin-C administration. *The Journal of dermatology*,

- 27(6), 413-415.
- 中村洋子 (2000). 【最新がん治療と看護】 化学療法と看護ケア:前編 がん化学療法の副作用対策 抗がん剤の血管外漏出とその対策. *がん看護*, 5(6), 476-479.
- 中山恭子, 佐々木美奈子, 永高朋子他 (2002). 化学療法ワーキンググループの取り組みと今後の課題: 看護部の活動報告. *県立がんセンター新潟病院医誌*, 41(2), 201-208.
- Nesti, S. P., & Kovac, R. (2000). 5-fluorouracil extravasation following port failure. *Journal of intravenous nursing : the official publication of the Intravenous Nurses Society*, 23(3), 176-180.
- 西澤健司, 木野毅彦 (2002). くすりと看護 血管外漏出によって障害を引き起こす可能性のある薬剤. *臨牀看護*, 28(7), 1133-1137.
- Nobbs, P., & Barr, R. D. (1983). Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. *British journal of cancer*, 48(6), 873-876.
- Nostdahl, T., & Waagsbo, N. A. (1998). Costoclavicular pinching: a complication of long-term central venous catheters. A report of three cases. *Acta anaesthesiologica Scandinavica*, 42(7), 872-875.
- Obrist, R., Haenggi, S. T., Heiman, D., & Obrecht, J. P. (1990). Localized skin toxicity from 5-fluorouracil after paravenous infusion of leukovorin calcium. *Annals of oncology*, 1(5), 384.
- Okano, T., Ohnuma, T., Efremidis, A., & Holland, J. F. (1983). Doxorubicin-induced skin ulcer in the piglet. *Cancer treatment reports*, 67(12), 1075-1078.
- Olver, I. N., Aisner, J., Hament, A., Buchanan, L., Bishop, J. F., & Kaplan, R. S. (1988). A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation. *Journal of Clinical Oncology*, 7, 1732-1735.
- ONS Clinical Practice Committee (1996). *Cancer chemotherapy guidelines and recommendations for practice-second edition* Pittsburgh. PA: Oncology Nursing Society, 28-51.
- 大沢徳哉他 (1999). マイトマイシン C による薬剤性皮膚壊死の経時的観察及びその治療について. *西日本皮膚科*, 61(3), 294-297.
- Patel, J. S., & Krusa, M. (1999). Distant and delayed mitomycin C extravasation. *Pharmacotherapy*, 19(8), 1002-1005.
- Perlin, E., & Ahlgren, J. D. (1991). Pigmentary effects from the protracted infusion of 5-fluorouracil. *International journal of dermatology*, 30(1), 43-44.
- Petro, J. A., Graham, W. P., 3rd., Miller, S. H., Overholt, T., & Fallon, T. (1979). Experimental and clinical studies of ulcers induced with adriamycin. *Surgical forum*, 30, 535-537.

- Poorter, R. L., Lauw, F. N., Bemelman, W. A., Bakker, P. J., Taat, C. W., & Veenhof, C. H. (1996). Complications of an implantable venous access device (Port-a-Cath) during intermittent continuous infusion of chemotherapy. *European journal of cancer* (Oxford, England : 1990), 32A(13), 2262-2266.
- Preuss, P., & Partoft, S. (1987). Cytostatic extravasations. *Annals of plastic surgery*, 19(4), 323-329.
- Puel, V., Caudry, M., Le, Metayer, P., Baste, J. C., Midy, D., Marsault, C., & Demeaux, H., et al. (1993). Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. *Cancer*, 72(7), 2248-2252.
- Raley, J., Geisler, J. P., Buekers, T. E., & Sorosky, J. I. (2000). Docetaxel extravasation causing significant delayed tissue injury. *Gynecol Oncol*, 78(2), 259-260.
- Reilly, J. J., Neifeld, J. P., & Rosenberg, S. A. (1977). Clinical course and management of accidental adriamycin extravasation. *Cancer*, 40(5), 2053-2056.
- Repelaer van Driel, O. J., Kuin, C. M., & van de Velde, C. J. (1988). Surgically implanted subcutaneous venous access devices in cancer patients. *The Netherlands journal of surgery*, 40(4), 97-99.
- Rinaldi, D. A., Lormand, N. A., Brierre, J. E., Cole, J. L., Staggs, M. P., Fontenot, M. F., Buller, E. J., & Rainey, J. M. (2000). A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no.1 (LOA-1). *American journal of clinical oncology: the official publication of the American Radium Society*, 23(1), 78-82.
- Rudolph, R., Stein, R. S., & Patillo, R. A. (1976). Skin ulcers due to Adriamycin. *Cancer*, 38, 1087-1094.
- Rudolph, R., Suzuki, M., & Luce, J. K. (1979). Experimental skin necrosis produced by adriamycin. *Cancer treatment reports*, 63(4), 529-537.
- Rudolph, R., Woodward, M., & Hurn, I. (1979). Ultrastructure of doxorubicin (adriamycin)-induced skin ulcers in rats. *Cancer research*, 39(9), 3689-3693.
- Saifi, J., MacDowell, R. T., Khouri, G., & Webster, D. J. (1987). In-situ breakage of an implantable venous access system. *European journal of surgical oncology*, 13(2), 159-162.
- 佐々木純, 加藤淳 (2001). 抗癌剤の血管外漏出. *medicina*, 38(9), 1516-1519.
- Satterwhite, B. E. (1980). What to do when adriamycin infiltrates. *Nursing*, 10(2), 37.
- 沢田幸正, 鈴木常正 (1984). 特異な経過をたどったマイトマイシン血管外漏出による皮膚潰瘍の1例. *臨床外科*, 39(4), 559-562.
- Shamseddine, A. I., Khalil, A. M., Kibbi, A. G., Abu Nasr, T. A., Seoud, M. A.-F., & Saghir, N. S. El (1998). Granulocyte macrophage-colony stimulating factor for

- treatment of chemotherapy extravasation. *European journal of gynaecological oncology*, 19(5), 479-481.
- Shapiro, J., & Richardson, G. E. (1994). Paclitaxel-induced "recall" soft tissue injury occurring at the site of previous extravasation with subsequent intravenous treatment in a different limb. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*, 12(10), 2237-2238.
- Shields, L. B., Hunsaker, D. M., & Hunsaker, J. C., 3rd. (2003). Iatrogenic catheter-related cardiac tamponade: a case report of fatal hydropericardium following subcutaneous implantation of a chemotherapeutic injection port. *Journal of forensic sciences*, 48(2), 414-418.
- 秦康博他 (1996). 当院における中心静脈カテーテル留置術の検討 特に P. A. S. port を用いた前腕部留置. *高知市医師会医学雑誌*, 1(1), 74-77.
- Soble, M. J., Dorr, R. T., Plezia, P., & Breckenridge, S. (1987). Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics. *Cancer chemotherapy and pharmacology*, 20(1), 33-37.
- Soh, L. T., Ang, P. T. (1993). Implantable subcutaneous infusion ports. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer, 1(2), 108-110.
- Sonneveld, P., Wassenaar, H. A., & Nooter, K. (1984). Long persistence of doxorubicin in human skin after extravasation. *Cancer treatment reports*, 68(6), 895-896.
- Spiegel, R. J. (1981). The acute toxicities of chemotherapy. *Cancer treatment reviews*, 8(3), 197-207.
- Standiford, S. B. (2001). Central venous access for chemotherapy. Michael C, Perry: *The Chemotherapy Source Book-Third Edition*, 559-566.
- Stanford, B. L., & Hardwicke, F. (2003). A review of clinical experience with paclitaxel extravasations. *Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer*, 11(5), 270-277.
- Stein, M. E., Drumea, K., Abu-Rasmi, R., & Haim, N. (1997). Taxol-induced cellulitis after extravasation: a rarely reported event. *American journal of clinical oncology: the official publication of the American Radium Society*, 20(5), 540.
- Strum, S., McDermed, J., Korn, A., & Joseph, C. (1986). Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system. *Journal of clinical oncology*, 4(4), 596-603.
- Svingen, B. A., Powis, G., Appel, P. L., & Scott, M. (1981). Protection against adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and alpha-tocopherol. *Cancer research*, 41(9 Pt 1), 95-99.

- Swartz, A. J. (1979). Chemotherapy extravasation management. Part I. Doxorubicin (Adriamycin). *Cancer Nursing*, 2(5), 405-407.
- 武田利明, 花里陽子, 石田陽子他 (2003). 薬剤の血管外漏出時のケア: 問題点と今後の課題. *看護技術*, 49(3), 244-247.
- 田村敦志 (1999). 点滴漏れによる皮膚障害. *診断と治療*, 87(増), 289-293.
- 田村敦志 (2003). 内科医が起こしうる皮膚疾患 点滴漏れ皮膚潰瘍. *medicina*, 40(6), 1002-1005.
- Tavecchio, L., Bedini, A. V., Lanocita, R., Patelli, G. L., Donati, I., & Ravasi, G. (1996). Long-term infusion in cancer chemotherapy with the Groshong catheter via the inferior vena cava. *Tumori*, 82(4), 372-375.
- Thurlimann, B., & Bachmann, I. (1992). Effective prevention of chemotherapy-induced phlebitis by low-dose heparin: a prospective randomised trial. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*, 3(4), 311-333.
- Torelli, G. F., Varma, M., & Meguid, M. M. (1999). Complication of subcutaneous insertion of Hickman catheter using the Seldinger technique in patient with pendulous breast. *Nutrition*, 15(6), 485-487.
- Tsavaris, N. B., Karagiaouris, P., Tzannou, I., Komitsopoulou, P., Bacoyiannis, C., Karabellis, A., Papanicolaou, V., Mylonakis, N., Karvounis, N., & Zoannou, A. et al., (1990). Conservative approach to the treatment of chemotherapy-induced extravasation. *The Journal of dermatologic surgery and oncology*, 16(6), 519-522.
- Tsavaris, N. B., Komitsopoulou, P., Karagiaouris, P., Loukatou, P., Tzannou, I., Mylonakis, N., & Kosmidis, P. (1992). Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach. *Cancer chemotherapy, & pharmacology*, 30(4), 330-333.
- Tschirhart, J. M., Rao, M. K. (1988). Mechanism and management of persistent withdrawal occlusion. *The American surgeon*, 54(6), 326-328.
- Ulutin, H. C., Guden, M., Dede, M., & Pak, Y. (2000). Comparison of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers. *European Journal of Gynaecol Oncol*, 21(6), 613-615.
- Umstead, G. S., Fryer, N. L., & Decker, D. A. (1991). Local tissue reaction to intravenous fluorouracil and leucovorin. *DICP: the annals of pharmacotherapy*, 25(3), 249-250.
- Upton, J., Mulliken, J. B., & Murray, J. E. (1979). Major intravenous extravasation injuries. *Am J Surg*, 137(4), 497-506.

- Upton, P. G., Yamaguchi, K. T., Myers, S., Kidwell, T. P., & Anderson, R. J. (1986). Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat. *Cancer treatment reports*, 70(4), 503-507.
- Vandeweyer, E., & Deraemaeker, R. (2000). Early surgical suction and washout for treatment of cytotoxic drug extravasations. *Acta chirurgica Belgica*, 100(1), 37-38.
- Vargel, I., Erdem, A., Ertoy, D., Pinar, A., Erk, Y., Altundag, M. K., & Gullu, I. (2002). Effects of growth factors on doxorubicin-induced skin necrosis: documentation of histomorphological alterations and early treatment by GM-CSF and G-CSF. *Annals of plastic surgery*, 49(6), 646-653.
- Viale, P. H. (2003). Complications associated with implantable vascular access devices in the patient with cancer. *Journal of infusion nursing*, 26(2), 97-102.
- Vogelzang, N. J. (1979). Adriamycin flare: a skin reaction resembling extravasation. *Cancer treatment reports*, 63, 2067.
- Vukelja, S. J., Bonner, M. W., McCollough, M., Cobb, P. W., Gaule, D. A., Fanucchi, P. J., & Keeling, J. H. (1991). Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil. *Journal of the American Academy of Dermatology*, 25(5 Pt 2), 905-908.
- 和田真弘他 (2005). 新規乳癌治療製剤としての paclitaxel 封入 MPC Polymer による抗癌剤の点滴漏出時の皮膚障害の抑制効果の比較検証. *日本外科学会雑誌*, 106, 561.
- Watterson, J., Heisel, M., Cich, J. A., & Priest, J. R. (1988). Intrathoracic extravasation of sclerosing agents associated with central venous catheters. *Am J Pediatr Hematol Oncol*, 10(3), 249-251.
- Webster, F. S. (2001). *Vascular Access Devices Clinical Guide to Antineoplastic Therapy: A chemotherapy Handbook*, 47-70.
- Wetmore, N. (1985). Extravasation. The dreaded complication. *NITA*, 8(1), 47-49.
- Wickham, R. S. (1990). Advances in venous access devices and nursing management strategies. *Nurs Clin North Am*, 25(2), 345-364.
- Wickham, R., Purl, S., & Welker, D. (1992). Long-term central venous catheters: issues for care. *Seminars in oncology nursing*, 8(2), 133-147.
- Wilson, J., Carder, P., Gooi, J., & Nishikawa, H. (1999). Recall phenomenon following epirubicin. *Clinical oncology (Royal College of Radiologists (Great Britain))*, 11(6), 424-425.
- Wolgemuth, R. L., Myers, C. A., Luce, J. K., Imondi, A. R., & Carrano, R. A. (1982). Doxorubicin extravasation ulceration: Animal model development and testing of potential antidotes. *American Association of Cancer Research*, 23, 171(abstract).

- Wood, H. A. (1984). Ellerhorst-Ryan JM. Delayed adverse skin reactions associated with mitomycin-C administration. *Oncology nursing forum*, 11(4), 14-18.
- Yama, N., Tsuchida, Y., Nuka, S., Kitagawa, S., & Saito, J. (2001). Usefulness of magnetic resonance imaging for surgical management of extravasation of an antitumor agent: a case report. *Japanese journal of clinical oncology*, 31(3), 122-124.
- 柳川茂他 (1992). 制癌剤漏出性皮膚障害の治療と予防法について—皮膚科医の役割. *臨床皮膚科*, 46 (5 増) , 169-174.
- Yilmaz, M., Demirdover, C., & Mola, F. (2002). Treatment options in extravasation injury: an experimental study in rats. *Plastic and reconstructive surgery*, 109(7), 2418-23.